Business Description
Xenon Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA98420N1050
Description
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 66.83 | |||||
| Equity-to-Asset | 0.95 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -57.2 | |||||
| 3-Year EPS without NRI Growth Rate | -50.2 | |||||
| 3-Year FCF Growth Rate | -15.4 | |||||
| 3-Year Book Growth Rate | 38.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -12.21 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.35 | |||||
| 9-Day RSI | 57.3 | |||||
| 14-Day RSI | 54.54 | |||||
| 6-1 Month Momentum % | 9.11 | |||||
| 12-1 Month Momentum % | 23.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 22.21 | |||||
| Quick Ratio | 22.21 | |||||
| Cash Ratio | 22.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.1 | |||||
| Shareholder Yield % | 0.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -26.06 | |||||
| ROA % | -24.96 | |||||
| ROIC % | -122.26 | |||||
| ROC (Joel Greenblatt) % | -1359.32 | |||||
| ROCE % | -30.86 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.05 | |||||
| Price-to-Tangible-Book | 4.05 | |||||
| EV-to-EBIT | -10.2 | |||||
| EV-to-EBITDA | -10.31 | |||||
| EV-to-Forward-Revenue | 1042.35 | |||||
| EV-to-FCF | -16.39 | |||||
| Price-to-Net-Current-Asset-Value | 5.2 | |||||
| Price-to-Net-Cash | 5.24 | |||||
| Earnings Yield (Greenblatt) % | -9.8 | |||||
| FCF Yield % | -4.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XENE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xenon Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.82 | ||
| Beta | 0.4 | ||
| Volatility % | 33.17 | ||
| 14-Day RSI | 54.54 | ||
| 14-Day ATR ($) | 1.576621 | ||
| 20-Day SMA ($) | 42.039 | ||
| 12-1 Month Momentum % | 23.79 | ||
| 52-Week Range ($) | 35.53 - 50.99 | ||
| Shares Outstanding (Mil) | 76.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xenon Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xenon Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xenon Pharmaceuticals Inc Frequently Asked Questions
What is Xenon Pharmaceuticals Inc(XENE)'s stock price today?
The current price of XENE is $42.63. The 52 week high of XENE is $50.99 and 52 week low is $35.53.
When is next earnings date of Xenon Pharmaceuticals Inc(XENE)?
The next earnings date of Xenon Pharmaceuticals Inc(XENE) is 2025-02-28 Est..
Does Xenon Pharmaceuticals Inc(XENE) pay dividends? If so, how much?
Xenon Pharmaceuticals Inc(XENE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers